ImageneBio, Inc. Common Stock (IMA) is a publicly traded Healthcare sector company. As of May 21, 2026, IMA trades at $5.41 with a market cap of $63.73M and a P/E ratio of -0.56. IMA moved +0.00% today. Year to date, IMA is -15.60%; over the trailing twelve months it is flat. Its 52-week range spans $3.94 to $18.00. Analyst consensus is buy with an average price target of $13.00. Rallies surfaces IMA's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
ImageneBio Raises $30M to Advance IMG-007 Trials in Alopecia Areata and Atopic Dermatitis: ImageneBio secured gross proceeds of $30 million through a private placement led by Coastlands Capital, issuing pre-funded warrants for up to 5,770,335 shares at $5.199 per warrant with a $0.001 exercise price. Funds will advance IMG-007’s alopecia areata program and late-stage trial activities in moderate-to-severe atopic dermatitis.
| Metric | Value |
|---|---|
| Price | $5.41 |
| Market Cap | $63.73M |
| P/E Ratio | -0.56 |
| EPS | $-9.64 |
| Dividend Yield | 0.00% |
| 52-Week High | $18.00 |
| 52-Week Low | $3.94 |
| Volume | 0 |
| Avg Volume | 0 |
| Revenue (TTM) | $800.00K |
| Net Income | $-45.35M |
| Gross Margin | 0.00% |
3 analysts cover IMA: 0 strong buy, 2 buy, 0 hold, 1 sell, 0 strong sell. Consensus rating is buy. Average price target: $13.00.